Segmental hemangioma of the head and neck: High prevalence of PHACE syndrome
To the Editor: PHACE syndrome was first described in 1996, as the association of posterior fossa abnormalities, plaque-type hemangioma of the head and neck ([5 cm), arterial anomalies, cardiovascular and eye abnormalities. 1 A consensus statement in 2009 widened the clinical description and set out diagnostic criteria. 1 Since 2009, all patients presenting to our department with plaque-type hemangioma of the head and neck have been referred for magnetic resonance imaging/magnetic resonance angiography (MRI/MRA) of the head and neck, echocardiogram, and ophthalmology review.
The primary aim of this study was to assess the prevalence of PHACE syndrome in this cohort. Secondary aims were (1) to describe their phenotypic features, focusing on whether the pattern of cutaneous distribution was related to adverse outcomes seen on MRI/MRA and identified on echocardiogram, and neurodevelopmental abnormalities, and (2) to document the outcome of treatment with propranolol in this group.
Records of all 50 patients with plaque-like infantile hemangioma (IH) referred for head and neck MRI/MRA between April 1, 2009, and March 31, 2014, were reviewed. Median age at presentation was 2 months, and median follow-up was 3 years. Using clinical photography, we evaluated the pattern of cutaneous involvement, classified using 2 published methods for mapping cutaneous vascular anomalies of the face. 2, 3 We reviewed echocardiogram and MRI/MRA findings, and assessed neurodevelopmental outcomes based on clinical and parental reporting. Associations between IH distribution and neurologic and cardiovascular outcomes were modeled using multiple logistic regression. Phenotypic characteristics of the cohort are demonstrated in Table I and characteristic MRI/MRA findings are illustrated in Fig 1. Fifty-eight percent of our cohort fulfilled the published criteria for PHACE syndrome, and 2% were diagnosed with possible PHACE syndrome. Sixty percent of children had an abnormal MRI/ MRA of the brain; however, there were no acute ischemic events, and 93% of those with abnormal imaging had normal neurodevelopment. This is in contrast to previous reports of higher incidence of abnormal neurodevelopment, 4 and could reflect the relatively short follow-up in this cohort so far. Abnormal echocardiogram findings were reported in 40% of patients, consistent with previous reports. 5 There were no statistical associations between cutaneous distribution of IH and abnormalities as seen on brain MRI/MRA or on echocardiogram.
Seventy-eight percent of our cohort was treated with propranolol following departmental guidelines for treatment of any IH compromising key anatomic structures. Sixty-nine percent received a treatment dose of 2 mg/kg/day. A 10% incidence of adverse effects was reported, necessitating change of treatment in 1 case and early weaning from therapy in another. There were no serious adverse events related to cardiovascular or cerebrovascular compromise.
In conclusion, the prevalence of PHACE syndrome in this cohort of children was high (58%), confirming that investigation for extracutaneous abnormalities in infants with plaque-like IH of the head and neck is an appropriate and necessary management strategy. There was no statistically significant link between the pattern of cutaneous involvement and cerebrovascular or cardiovascular abnormalities. Funding sources: None. 
